The results showed that the combination therapy with BIBR1532 and NK cells significantly increased the expression of Bax protein in both primary AML and Kg-1a cells in comparison to monotherapy (Fig. 6A–C). This evidence concerns the gene BAX and acute myeloid leukemia.